Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316202 | 0.85 | KAT2B (0.36) | KDM4EKDM5AMTNR1AMTNR1BKDM4D | |
| SCHEMBL30566050 | 0.85 | KDM4E (0.38) | KDM4EKDM5AGRM7 | |
| SCHEMBL16078081 | 0.84 | KDM5A (0.45) | KDM4EKDM5AMTNR1AMTNR1BKDM4D | |
| SCHEMBL13192995 | 0.84 | KDM5A (0.45) | KDM4EKDM5AMTNR1AMTNR1BKDM4D | |
| SCHEMBL18347953 | 0.84 | KDM5A (0.45) | KDM4EKDM5AMTNR1AMTNR1BKDM4D | |
| SCHEMBL16665763 | 0.84 | KDM4E (0.33) | KDM4EKDM5AMTNR1AMTNR1BKDM4D | |
| SCHEMBL10208257 | 0.83 | KDM4E (0.37) | KDM4EGRM7 | |
| SCHEMBL25161166 | 0.83 | KDM4E (0.37) | KDM4EGRM7 | |
| SCHEMBL22965461 | 0.82 | KAT2B (0.34) | KDM4EKDM5A | |
| SCHEMBL12304472 | 0.81 | KDM4E (0.50) | KDM4EKDM5AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | EXELIXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022074459-A2 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-14 | — | — | WO | disclosed |
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2022-03-24 | — | — | US | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3581576-B1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS FOR USE IN THE TREATMENT OF A PROLIFERATIVE DISEASE IN COMBINATION WITH A JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2021-02-11 | — | — | US | disclosed |
| EP-3616753-A1 | COMPOUNDS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | Corvus Pharmaceuticals, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-2809652-B1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-20150166569-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-9034866-B2 | Tricyclic compounds and methods of use therefor | GENENTECH, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | GENENTECH, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | GENENTECH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275030-A1 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS | BRD1, BRD3, BRD2 | KDM4E 1807/4885KDM5A 2823/4885MTNR1A 4252/4885 |
| US-20150166569-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | KDM4E 3930/4885KDM5A 3327/4885MTNR1A 153/4885 |
| US-11542259-B2 | Compounds for the treatment of kinase-dependent disorders | ERBB2, MAP3K6, MAP3K1 | KDM4E 2704/4885KDM5A 3709/4885MTNR1A 626/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | KDM4E 2058/4885KDM5A 2169/4885MTNR1A 2436/4885 |
| US-20140343036-A1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | NQO1, NDUFC2, NDUFV2 | KDM4E 3019/4885KDM5A 2759/4885MTNR1A 1696/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | KDM4E 2058/4885KDM5A 2169/4885MTNR1A 2436/4885 |
| US-20210040076-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, MAP3K1 | KDM4E 2704/4885KDM5A 3709/4885MTNR1A 626/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | KDM4E 1997/4885KDM5A 2217/4885MTNR1A 4428/4885 |
| US-20220089593-A1 | PDE9 INHIBITOR AND USE THEREOF | PDE9A, PDE12, PDE5A | KDM4E 571/4885KDM5A 362/4885MTNR1A 1242/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KDM4E 2058/4885KDM5A 2169/4885MTNR1A 2436/4885 |
| US-20130217666-A1 | TRICYCLIC COMPOUNDS AND METHODS OF USE THEREFOR | NFKB1, NFKBIA, RELA | KDM4E 3930/4885KDM5A 3327/4885MTNR1A 153/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | KDM4E 2058/4885KDM5A 2169/4885MTNR1A 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.